

To: Business Editor
[For immediate release]



Lee's Pharmaceutical Holdings Limited

李氏大藥廠控股有限公司

Lee's Pharm Joins Hang Seng Broad Consumption Index, Hang Seng Mainland Consumer Goods Index, Hang Seng Global Composite Index and Hang Seng Composite Index

* * * * *

Enhances The Reputation And Position Of The Group In The International Capital Market

[6 March 2015 - Hong Kong] Lee's Pharmaceutical Holdings Limited ("Lee's Pharm" or the "Company", Stock Code: 950, together with its subsidiaries, the "Group"), an integrated research-driven and market-oriented pharmaceutical group in China, is pleased to announce that the Company has been selected by Hang Seng Indexes Company Limited as a constituent of the Hang Seng Broad Consumption Index ("HSBCI"), Hang Seng Mainland Consumer Goods Index ("HSMCGI"), Hang Seng Global Composite Index ("HSGCI") and Hang Seng Composite Index ("HSCI") Series including: Hang Seng Composite Index, Hang Seng Composite Industry Index – Consumer Goods and Hang Seng Composite SmallCap Index, with effect from 9 March 2015 (Monday).

There is a strict selection program for Hang Seng Family of Indexes, with a high standard for the total market capitalization, trading volume, financial condition, influence and position in the industry of the selected company.

Dr. Benjamin Li, Executive Director and Chief Executive Officer of the Group, said, "HSBCI, HSMCGI, HSGCI and HSCI are comprehensively recognized, and are important benchmark indexes in the global capital market which numerous sizable funds and investment portfolios refer to. The Group is proud of being included into these indexes, which proves our position in the global capital market as well as the recognition of the Group in pharmaceutical industry. Being one of the constituent

博達浩華國際財經傳訊集團

Porda Havas International Finance Communications Group

Units 2009-2018, 20/F, Shui On Centre, 6-8 Harbour Road, Wanchai, HK 香港灣仔港灣道6-8號瑞安中心20樓2009-2018室
T : (852) 3150 6788 F : (852) 3150 6728

stocks of these important benchmark indexes not only further enhance our corporate image, but also help investors to better assess future development potential of the Group. We would like to extend the sincere gratitude to investors and the community for their long-standing trust and support, and we will continue to enhance the transparency of corporate governance and strive for better performance, generating the best possible returns for our shareholders.”

- End -

About Lee's Pharmaceutical Holdings Limited

Lee's Pharm is a research-based biopharmaceutical company listed in Hong Kong with over 20 years operation in China's pharmaceutical industry. It is fully integrated with strong infrastructures in drug development, manufacturing, sales and marketing. It has established extensive partnership with over 20 international companies and currently has 14 products in the market place. Lee's Pharm focuses on several key disease areas such as cardiovascular diseases, oncology, gynecology, dermatology and ophthalmology. Lee's Pharm development program is lauded with 30 products stemming from both internal R&D efforts and collaborations with US, European and Japanese companies and aspires to combat diseases such as liver cancer and pulmonary hypertension. The mission of Lee's Pharm is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life.

Additional information about Lee's Pharm is available at www.leespharm.com.

Additional information about Hang Seng Index is available at www.hsi.com.hk.

Issued by Porda Havas International Finance Communications Group for and on behalf of **Lee's Pharmaceutical Holdings Limited**. For further information, please contact:

Porda Havas International Finance Communications Group

Keely Chan	+852 3150 6760	keely.chan@pordahavas.com
Cherry Cheung	+852 3150 6773	cherry.cheung@pordahavas.com
Sophie Zhang	+852 3150 6742	sophie.zhang@pordahavas.com
Mandy Zhang	+852 3150 6765	mandy.zhang@pordahavas.com

博達浩華國際財經傳訊集團

Porda Havas International Finance Communications Group

Units 2009-2018, 20/F, Shui On Centre, 6-8 Harbour Road, Wanchai, HK 香港灣仔港灣道6-8號瑞安中心20樓2009-2018室
T : (852) 3150 6788 F : (852) 3150 6728



Claire Li +852 3150 6711 claire.li@pordahavas.com

Fax: +852 3150 6728

博達浩華國際財經傳訊集團

Porda Havas International Finance Communications Group

Units 2009-2018, 20/F, Shui On Centre, 6-8 Harbour Road, Wanchai, HK 香港灣仔港灣道6-8號瑞安中心20樓2009-2018室
T : (852) 3150 6788 F : (852) 3150 6728

www.pordahavas.com